BioSpace News Archive

On 14th, MEDICOX, listed on KOSDAQ, signed an exclusive distribution contract with an oral drug delivery platform developer, ORAMED Pharmaceuticals on the oral insulin license.

Orthofix and SeaSpine announced that John Bostjancic will serve as Chief Financial Officer for the new combined company, effective upon the completion of their pending merger.

Apellis Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted Apellis’ unsolicited major amendment to the New Drug Application (NDA) for intravitreal pegcetacoplan for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Eczacıbaşı-Monrol Nuclear Products Co. (Monrol) is delighted to announce that it has reached an agreement in principal with FutureChem based in Seoul, South Korea to support FutureChem’s Investigational New Drug IND-enabling Phase 2 clinical trial with Ludotadipep, 177 Lu-FC705.

KemPharm, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted the Orphan Drug Designation to serdexmethylphenidate (SDX), KemPharm’s proprietary prodrug of d-methylphenidate (d-MPH), for the treatment of idiopathic hypersomnia (IH), a rare neurological sleep disorder.

Twist Bioscience Corporation today reported financial results and business highlights for the fourth quarter and full year fiscal 2022 ended September 30, 2022.

Berkeley Lights, Inc., a leader in digital cell biology, announced the launch of the Opto® Memory B Discovery Rabbit workflow, expanding the diversity of antibodies customers can discover on the Beacon® platform.

Candel Therapeutics, Inc. (“Candel” or “the Company”) (Nasdaq: CADL) today announced presentation of updated data from a phase 1 clinical trial of CAN-3110 in patients with recurrent high-grade glioma (rHGG).

electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that gammaCore Sapphire has been issued a National Code Number (CNK) in Belgium.

The company announced the first phase of the set of in vitro experiments designed to accomplish this validation was successful.